Risk of Injuries Up Around Period of Cancer Diagnosis

Share this content:
Risk of Injuries Up Around Period of Cancer Diagnosis
Risk of Injuries Up Around Period of Cancer Diagnosis

FRIDAY, Sept. 2, 2016 (HealthDay News) -- Patients with cancer have increased risks of iatrogenic and non-iatrogenic injuries shortly before and after cancer diagnosis, according to a study published online Aug. 31 in The BMJ.

Qing Shen, from the Karolinska Institutet in Stockholm, and colleagues examined the risks of iatrogenic and non-iatrogenic injuries before and after cancer diagnosis using data from Swedish national population and health registers. Data were included for 720,901 patients with a cancer diagnosis from 1991 to 2009.

The researchers identified 7,306 iatrogenic and 8,331 non-iatrogenic injuries during the diagnostic period (incidence rates, 0.60 and 0.69 per 1,000 person-months, respectively). Compared with the pre-diagnostic period, during the diagnostic period the incidence rate ratio for iatrogenic injuries was 7.0. The increase in risk started two weeks prior to diagnosis of cancer and peaked during the two weeks following diagnosis (48.6). The incidence rate ratio was 1.9 during the diagnostic period versus the pre-diagnostic period for non-iatrogenic injuries. The risk began to increase four weeks pre-diagnosis and peaked during the two weeks preceding diagnosis (incidence rate ratio, 5.3). For all common cancers there were increased risks for both types of injury during the diagnostic period, with the smallest risk increase for non-melanoma skin cancer.

"These findings shed further light on the total burden of medical complications and call for prevention of intentional and unintentional injuries during the diagnostic process of cancer," the authors write.

Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »